Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
Quarantine is an unpleasant experience : separation from loved ones, loss of freedom, uncertainty about infection status, boredom. It may lead to negative mental health consequences and thus the emergence of anxiety and depressive symptoms. From March 17th, 2020 to May 11th 2002, the French government has implemented national containment measures due to the Covid-19 epidemic. Although there are data on the psychological impact and experience of quarantine measures in people who have been infected or suspected of being carriers of certain pathogens (e.g. Ebola), there are no data on such impact in the French population and quarantines lasting longer than 21 days. Investigators therefore propose to conduct a human and social sciences study in order to better understand the current situation
Description: depressive symptomatology with Patient Health Questionnaire : PHQ-9 scale (PHQ 9 higher score, more depressive -> min : 0 max : 27)
Measure: Depressive Symptomatology Time: during confinementDescription: depressive symptomatology with Patient Health Questionnaire : PHQ-9 scale (PHQ 9 higher score, more depressive -> min : 0 max : 27)
Measure: Depressive Symptomatology Time: post-confinement : 15 days, 3 months, 6 monthsDescription: Psychological pain : likert scale (higher score, more psychological pain-> min : 0 max : 10)
Measure: Psychological pain Time: during confinementDescription: quality of sleep assessed with Insomnia Seveity Index (ISI Insomnia Severity Scale ; higher score, more insomnia -> min : 0 max : 28)
Measure: sleep Time: during confinementDescription: quality of sleep assessed with Insomnia Seveity Index (ISI Insomnia Severity Scale ; higher score, more insomnia -> min : 0 max : 28)
Measure: sleep Time: post-confinement (15 days, 3 months, 6 months)Description: anxiety intensity assessed by Generalized Anxieety Disorder (GAD 7 Generalized Anxiety Disorder higher score, more anxious -> min : 0 max : 21)
Measure: anxiety Time: during confinementDescription: anxiety intensity assessed by Generalized Anxieety Disorder (GAD 7 Generalized Anxiety Disorder higher score, more anxious -> min : 0 max : 21)
Measure: anxiety Time: post-confinement (15 days, 3 months, 6 months)Description: psychological pain : likert scale (higher score, more psychological pain-> min : 0 max : 10)
Measure: psychological pain Time: post-confinement (15 days, 3 months, 6 months)Description: psychological pain : likert scale (higher score, more psychological pain-> min : 0 max : 10)
Measure: physical pain Time: during confinementDescription: psychological pain : likert scale higher score, more psychological pain-> min : 0 max : 10)
Measure: physical pain Time: post-confinement (15 days, 3 months, 6 months)Description: staxi state scale (STAXI ; State and Trait Anger Expression Inventory : higher score, more anger -> min : 0 max : 50)
Measure: anger Time: during confinementDescription: staxi state scale (STAXI ; State and Trait Anger Expression Inventory : higher score, more anger -> min : 0 max : 50)
Measure: anger Time: post-confinement (15 days, 3 months, 6 months)Description: Assessed by the Stressful Event Impact Scale - Horowitz (HOROWITZ higher score, more traumatizes -> min : 0 max : 45) )
Measure: Stressful Event Impact Time: during confinementDescription: Assessed by the Stressful Event Impact Scale - Horowitz (HOROWITZ higher score, more traumatizes -> min : 0 max : 45)
Measure: Stressful Event Impact Time: post-confinement (15 days, 3 months, 6 months)Description: Number of patients declaring an increase of psychotropic drug use
Measure: Use of psychotropic drugs Time: during confinementDescription: Number of patients declaring an increase of psychotropic drug use
Measure: Use of psychotropic drugs Time: post-confinement (15 days, 3 months, 6 months)Description: Number of patients declaring an increase of tobacco consumption
Measure: Tobacco consumption Time: during confinementDescription: Number of patients declaring an increase of tobacco consumption
Measure: Tobacco consumption Time: post-confinement (15 days, 3 months, 6 months)Description: Number of patients declaring an increase of alcohol consumption
Measure: alcohol consumption Time: post-confinement (15 days, 3 months, 6 months)Description: Number of patients declaring an increase of alcohol consumption
Measure: alcohol consumption Time: confinementDescription: Number of patients declaring an increase of illicit substances consumption
Measure: Illicit substances consumption Time: confinementDescription: Number of patients declaring an increase of illicit substances consumption
Measure: Illicit substances consumption Time: post-confinement (15 days, 3 months, 6 months)Description: Life Orinetation Test Revised (LOT-R questionnaire): higher score, more optimistic --> min : 0 max : 24
Measure: orientation of life Time: confinementDescription: Life Orinetation Test Revised (LOT-R questionnaire): higher score, more optimistic --> min : 0 max : 24
Measure: orientation of life Time: post-confinement (15 days, 3 months, 6 months)Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports